Tumor Necrosis Factor Inhibiotrs Market & Clinical Pipeline Outlook 2022

Date: November 1, 2016
Pages: 600
Price:
US$ 2,400.00
License [?]:
Publisher: Kuick Research
Report type: Strategic Report
Delivery: E-mail Delivery (PDF), Hard Copy Mail Delivery, CD-ROM Mail Delivery
ID: T8ACBD30B72EN
Leaflet:

Download PDF Leaflet

Tumor Necrosis Factor Inhibiotrs Market & Clinical Pipeline Outlook 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

“Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022” report by KuicK Research analyzes ongoing clinical and non-clinical trends in the global Tumor Necrosis Factor Inhibitors market. The anti TNF drugs are among the top 10 global block buster drugs and have dominated the global pharmaceutical market landscape for many years. The anti TNF Drugs (Humira, Remicade & Enbrel) for Rheumatic Disease have combined sales of more than US$ 30 Billion in 2015. The multiple approaches used in development of Anti-TNF drugs along with the function of Tumor Necrosis Factor in Immune Mediated Inflammatory Diseases, Neurodegenerative Disorders and development of Cancer are explained in the report. Currently there are 151 Tumor Necrosis Factor Inhibitors in clinical pipeline and 25 Tumor Necrosis Factor Inhibitors are commercially available in the market.

Tumor Necrosis Factor consists of a pleiotropic cytokine, regulating various cellular and biological events such as immune and inflammatory responses, cell differentiation and proliferation, apoptosis and energy metabolism. The cellular source of TNF depends on the nature of the stimulus. Tumor necrosis factor is produced primarily by the cells of hematopoietic origin, including myeloid lineage such as monocyte and macrophages.

Over the past decade the pharmaceutical agents directed against TNF-?, infliximab, adalimumab and Etanercept, have been widely and successfully employed for the management of rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriasis, psoriatic arthritis, juvenile idiopathic arthritis and inflammatory bowel disease, and however two novel anti-TNF-? agents such as golimumab and certolimumab pegol, recently entered the market for the treatment of RA, AS, Crohn's disease and psoriasis.

The encouragement of the research by the positive results obtained from the use of TNF-? antagonists in terms of efficacy and safety and due to the increasingly collecting the evidence regarding the implication of TNF-? in the pathogenesis of numerous disorders and the anti-TNF-? agents have been considered for the management of diseases other than the ones they were initially approved for.

Anti-tumor necrosis factor (TNF) therapy is a valid, effective and increasingly used option in inflammatory bowel disease management. However, the further knowledge and therapeutic indications regarding the drugs are still growing. Anti-TNF therapy may be essential to achieve the recently projected end points and the prevention of bowel damage and prevention of patient's disability.

Anti-TNF drugs are also recommended to be more operative in early disease, particularly in early Crohn's disease. Moreover, its efficiency for prevention of postoperative recurrence in Crohn's disease is still debated. Costs and adverse effects, the significance of drug monitoring and the possibility of anti-TNF therapy withdrawal in selected patients are still debated issues. The reviews are expected to describe and discuss the most relevant data about the progress with anti-TNF therapy for the organization of inflammatory bowel disease.

“Tumor Necrosis Factor Inhibitors Market & Clinical Pipeline Outlook 2022” Report Highlight:
  • Overview of Tumor Necrosis Factor Inhibitors
  • Approaches Used in Development of Anti-TNF
  • TNF Inhibitors Market Overview
  • Tumor Necrosis Factor as an Anti-Cancer Agent
  • Global Tumor Necrosis Factor Inhibitors Pipeline by Company, Indication & Phase
  • Global Tumor Necrosis Factor Inhibitors Pipeline: 151
  • Marketed Tumor Necrosis Factor Inhibitors: 25
1. INTRODUCTION TO TUMOR NECROSIS FACTOR (TNF)

1.1 Basic Structure of the Tumor Necrosis Factor (TNF) Molecule
1.2 Significance of Tumor Necrosis Factor for the Biosynthesis Regulation
  1.2.1 Regulation of TNF Biosynthesis at the Transcriptional Level
  1.2.2 Regulation the TNF at the Receptor Level
1.3 Tumor Necrosis Factor Receptors

2. TUMOR NECROSIS FACTOR RECEPTOR SIGNALING PATHWAY

2.1 Tumor Necrosis Factor Receptor1 (TNFR1) Signaling
2.2 Tumor Necrosis Factor Receptor 2 (TNFR 2) Signaling

3. OVERVIEW OF TUMOR NECROSIS FACTOR INHIBITORS

3.1 Mechanism of Action of Tumor Necrosis Factor Inhibitors
3.2 Mechanism of Action of Remicade in the Inflammatory Diseases
3.3 Mechanism of Action of the Etanercept
3.4 Mechanism of Action of Humira

4. APPROACHES USED IN DEVELOPMENT OF ANTI-TNF

4.1 Monoclonal Antibody Approach
4.2 Recombinant DNA Technology Approach

5. FUNCTION OF TNF IN IMMUNE MEDIATED INFLAMMATORY DISEASES

5.1 Rheumatoid Arthritis
5.2 Crohn's Disease
5.3 Psoriasis & Psoriatic Arthritis

6. INVOLVEMENT OF TNF & ITS RECEPTOR IN NEURODEGENERATIVE DISORDERS

6.1 Alzheimer’s Diseases
6.2 Parkinson’s Diseases
6.3 Ischemic Stroke
6.4 Multiple Sclerosis

7. ROLE OF THE TUMOR NECROSIS FACTOR IN THE DEVELOPMENT OF THE CANCER

7.1 Introduction
7.2 Tumor Necrosis Factor as Carcinogen
7.3 Tumor Necrosis Factor as an Anti-Cancer Agent

8. TNF INHIBITORS MARKET OVERVIEW

8.1 Market of Anti-TNF Blockbuster Drugs
  8.1.1 Market of Humira
  8.1.2 Market of Enbrel
  8.1.3 Market of Remicade
8.2 Global Tumor Necrosis Factor Inhibitors Pipeline Overview

9. GLOBAL TNF INHIBITORS MARKET DYNAMICS

9.1 Accelerative Parameters to the TNF Inhibitor Market
9.2 Challenges to the TNF Inhibitor Market

10. FUTURE IMPLICATIONS OF TNF INHIBITOR MARKET

11. GLOBAL TUMOR NECROSIS FACTOR INHIBITORS PIPELINE BY COMPANY, INDICATION & PHASE

11.1 Unknown
11.2 Research
11.3 Preclinical
11.4 Clinical
11.5 Phase-I
11.6 Phase-I/II
11.7 Phase-II
11.8 Phase-II/III
11.9 Phase-III
11.10 Preregistration
11.11 Registered

12. MARKETED TUMOR NECROSIS FACTOR INHIBITORS CLINICAL INSIGHT

12.1 Lumbricus Rubellus Extract (Disolf)
12.2 Certolizumab Pegol (Cimzia, Simziya)
12.3 Apremilast (Otezla)
12.4 Lenalidomide (Ladevina, Revlimid)
12.5 Adalimumab (Humira, Raheara)
12.6 Etanercept (Enbrel)
12.7 Infliximab Biosimilar (Inflectra, Remsima)
12.8 Adalimumab Biosimilar
12.9 Pomalidomide (Imnovid, Pomalyst)
12.10 Belimumab (Benlysta)
12.11 Etanercept Biosimilar (Infinitam)
12.12 Golimumab (Simponi)
12.13 Infliximab Biosimilar (Infimab)
12.14 Infliximab (Remicade)
12.15 Etanercept Biosimilar (Intacept)
12.16 Iguratimod (Careram, Kolbet)
12.17 Thalidomide (Thaled, Thalidomide Celgene, Thalomid)
12.18 Infliximab Biosimilar
12.19 Adalimumab Biosimilar (Exemptia)
12.20 Etanercept Biosimilar (Iran)
12.21 Etanercept Biosimilar (Etacept, Etanar, Yisaipu)
12.22 Iguratimod
12.23 Anti-Tumour Necrosis Factor-Alpha Antibody Oral
12.24 Pentoxifylline (Claudicat, Dospan Pento, Elorgan, Pentoxifilina, Trental)
12.25 Sho-seiryu-to

13. TNF INHIBITORS SUSPENDED IN CLINICAL PIPELINE

13.1 No Development Reported
13.2 Discontinued
13.3 Suspended

14. COMPETITIVE LANDSCAPE

14.1 AbbVie
14.2 Ablynx
14.3 Apogenix
14.4 AryoGen Biopharma
14.5 Bionovis
14.6 CASI Pharmaceuticals
14.7 Celltrion
14.8 Celgene Corporation
14.9 Delenex Therapeutics
14.10 Dexa Medica
14.11 EPIRUS Biopharmaceuticals
14.12 Janssen Biotech
14.13 GlaxoSmithKline
14.14 HanAll Biopharma
14.15 Intas Pharmaceuticals
14.16 LEO Pharma
14.17 LG Life Sciences
14.18 MedImmune
14.19 Momenta Pharmaceuticals
14.20 Novartis
14.21 PROBIOMED
14.22 Reliance Life Sciences
14.23 Sandoz
14.24 Samsung Bioepis
14.25 Sanofi-Aventis
14.26 Shanghai CP Guojian Pharmaceutical
14.27 Shanghai Pharmaceuticals
14.28 Simcere Pharmaceutical
14.29 Toyama Chemical
14.30 Tsumura
14.31 UCB
14.32 Zydus Cadila

LIST OF FIGURES

Figure 1-1: Structure of the Tumor Necrosis Factor Molecule
Figure 1-2: Regulation of the Tumor Necrosis Factor Biosynthesis & Bioavailability
Figure 1-3: Structure of Tumor Necrosis Factor Receptor
Figure 1-4: Structure of Tumor Necrosis Factor Receptor
Figure 2-1: Signaling Pathway of Tumor Necrosis Factor Receptor1 (TNFR1)
Figure 2-2: Tumor Necrosis Factor Receptor 2 Signaling Pathway (TNFR 2)
Figure 3-1: Remicade Mechanism of Action
Figure 3-2: Etanercept Mode of Action
Figure 3-3: Humira Mechanism of Action
Figure 4-1: Methods for the Anti-TNF Production
Figure 5-1: Tumor Necrosis Factor in Rheumatoid Arthritis
Figure 5-2: Global - Top Anti-Rheumatic Drug Sales (US$ Million), 2015 & 2022
Figure 5-3: Anti-TNF Therapy for the Treatment of Rheumatoid Arthritis
Figure 5-4: Molecular Targets of TNF Antagonists in Crohn’s Disease
Figure 5-5: Tumor Necrosis Factor in Psoriatic Arthritis
Figure 7-1: Tumor Necrosis Factor in the Cancer Initiation
Figure 7-2: Role of Tumor Necrosis Factor as an Anti-Cancer Agent
Figure 8-1: Blockbuster Anti-TNF Drugs (US$ Billion), 2015
Figure 8-2: Blockbuster TNF Inhibitors for Rheumatic Disease (US$ Billion), 2015 & 2022
Figure 8-3: Humira - Global Sales (US$ Billion), 2011-2015 & 2022
Figure 8-4: Enbrel - Global Sales (US$ Billion), 2011-2015 & 2022
Figure 8-5: Market Price of Enbrel & Etacept (USD)
Figure 8-6: Remicade - Global Sales (US$ Billion), 2011-2015 & 2022
Figure 8-7: Market Price of Remicade & Infimab (USD)
Figure 8-8: Global - Tumor Necrosis Factor Inhibitors Pipeline by Phase (%), 2016 till 2022
Figure 8-9: Global - Tumor Necrosis Factor Inhibitors Pipeline by Phase (Numbers), 2016 till 2022
Figure 8-10: Global - Tumor Necrosis Factor Inhibitors Suspended & Discontinued in Pipeline by Phase (%), 2016
Figure 8-11: Global - Tumor Necrosis Factor Inhibitors Suspended & Discontinued in Pipeline by Phase (Number), 2016
Figure 9-1: Favorable Parameters of Anti-TNF Drugs
Figure 9-2: Limitation Factors for the Anti-TNF Drug Market
Figure 14-1: Ablynx - Clinical Pipeline
Figure 14-2: Apogenix - Clinical Pipeline
Figure 14-3: Casi Pharmaceutical - Clinical Pipeline
Figure 14-4: Celgene - Clinical Pipeline
Figure 14-5: EPIRUS Biopharmaceuticals - Clinical Pipeline
Figure 14-6: HanAll Biopharma - Clinical Pipeline
Figure 14-7: Novartis - Clinical Pipeline
Figure 14-8: Sandoz - Clinical Pipeline
Figure 14-9: Toyama Chemical - Clinical Pipeline
Figure 14-10: Zydus Cadila - Clinical Pipeline
Skip to top


Ask Your Question

Tumor Necrosis Factor Inhibiotrs Market & Clinical Pipeline Outlook 2022
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: